DDInter1938 DDInter905
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Netupitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Voacamine
Voacamine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Netupitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Vindesine
Vindesine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Vincristine {u} (Compound) treats {v} (Disease) muscle cancer
muscle cancer {u} (Disease) is treated by {v} (Compound) Dactinomycin
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may lead to a major life threatening interaction when taken with Idelalisib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may lead to a major life threatening interaction when taken with Idelalisib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Vincristine (Compound) resembles Voacamine (Compound) and Voacamine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may lead to a major life threatening interaction when taken with Idelalisib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Vincristine (Compound) resembles Vindesine (Compound) and Vindesine (Compound) resembles Vinblastine (Compound) and Vinblastine may lead to a major life threatening interaction when taken with Idelalisib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Vincristine (Compound) treats muscle cancer (Disease) and muscle cancer (Disease) is treated by Dactinomycin (Compound) and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib